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S U M M A R Y
Background: The purpose of this study was to determine the species distribution and to monitor the
antifungal susceptibility proﬁles of clinical Candida isolates collected in China from 2009 to 2013.
Methods: The antifungal susceptibilities of 952 Candida isolates were tested.
Results: Candida albicans was the most common species, accounting for 65.7% of the total isolates. The
most frequently isolated non-albicans Candida species in this study was Candida glabrata (193, 20.3%).
Nearly 7.6%, 3.2%, 1.8%, and 1.1% of the 952 isolates exhibited decreased susceptibility to ﬂuconazole,
voriconazole, itraconazole, and ﬂucytosine, respectively. Moreover, seven C. albicans and one Candida
krusei had an amphotericin B minimum inhibitory concentration (MIC) of 2 mg/ml.
Conclusions: The distribution of species and the prevalence of antifungal resistance in Candida isolates
varied among different areas in China. Continuous monitoring of resistance patterns is necessary to
control the spread of resistance in clinical isolates of Candida species.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Candida species are commonly isolated fungal pathogens that
are responsible for many types of fungal infection in immunocom-
promised patients and hospitalized patients with serious underly-
ing diseases.1,2 Azole drugs are the most prescribed antifungal
agents for the treatment of such infections in clinical practice.3
However, with long-term therapies, azole resistance often emerges
in Candida isolates, especially Candida albicans, resulting in
therapeutic failures.3,4 In addition, the species distribution and
antifungal resistance among Candida isolates vary from region to
region.5,6 Thus, it is important for clinicians to understand the local
antifungal susceptibility proﬁles of Candida spp before treatment is
initiated.
In order to provide effective guidelines for the treatment of
candidiasis, we conducted this study to determine the distribution
of Candida species and to monitor the antifungal susceptibility
proﬁles of these isolates collected annually in September during
the years 2009 to 2013 in Anhui, China.* Corresponding authors. Tel.: +86 55162283823; fax: +86 55162283823.
E-mail addresses: biyoushenghua@sohu.com (J. Li), 98zl@sina.com (B. Liu).
http://dx.doi.org/10.1016/j.ijid.2014.12.033
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).2. Materials and methods
2.1. Isolates and identiﬁcation
A total of 952 non-duplicate Candida isolates were collected
from different sites from 952 patients who received treatment at
their local hospital in different geographic regions of Anhui, China.
All clinical specimens were incubated and isolated on Sabouraud
dextrose agar (Oxoid) with chloramphenicol (50 mg/ml). Species
identiﬁcation was performed with CHROMagar Candida and the
API 20C AUX system (bioMe´rieux, France) in accordance with the
manufacturer’s instructions, supplemented by conventional meth-
ods when needed.7 All isolates were stored as suspensions in water
until used in this study. To ensure optimal growth characteristics,
each isolate was subcultured twice on Sabouraud dextrose agar at
35 8C before susceptibility testing.
2.2. Antifungal susceptibility testing
In vitro antifungal susceptibility testing of Candida isolates
was performed by broth microdilution method according to the
M27-A3 guidelines of the Clinical and Laboratory Standards
Institute (CLSI).8 The dilution of the yeasts was conducted inciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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0.5–2.5  103 cells/ml. The drug concentrations of amphotericin B,
ﬂucytosine, and azoles (ﬂuconazole, itraconazole, and voriconazole)
obtained from Bristol-Myers Squibb, Sigma, and Pﬁzer, respectively,
were prepared as described in CLSI document M27-A3.8 Following
incubation at 35 8C for 24 h, the minimum inhibitory concentration
(MIC) was deﬁned as the lowest concentration of drug that caused
more than 50% inhibition of growth for ﬂucytosine and azoles, and
completely inhibited cell growth for amphotericin B. The clinical
breakpoints determined by 24-h CLSI broth microdilution method
have been newly revised to provide species-speciﬁc interpretive
criteria for the ﬁve most common Candida species (C. albicans,
Candida glabrata, Candida tropicalis, Candida krusei, and Candida
parapsilosis),9,10 and they were adopted in this study. Given the
absence of clinical breakpoints for some uncommon species, we
applied the epidemiological cut-off values (ECVs) instead to detect
the emergence of potential resistance to antifungal agents.9
Interpretive criteria for susceptibility to antifungal agents were
as follows: for ﬂuconazole, MICs 2 mg/ml were considered
susceptible for C. albicans, C. tropicalis, and C. parapsilosis after
24 h of incubation, and MICs 8 mg/ml were resistant, 4 mg/ml
susceptible-dose dependent (SDD). For C. glabrata, a ﬂuconazole MIC
32 mg/ml was considered SDD, while 64 mg/ml was considered
resistant. For voriconazole, MICs 0.125 mg/ml, 0.25–0.5 mg/ml,
and 1 mg/ml were considered susceptible, intermediate, and
resistant, respectively, for C. albicans, C. tropicalis, and C. parapsilosis,
whereas the clinical breakpoints for C. krusei were MICs 0.5 mg/ml
susceptible, 2 mg/ml resistant, and 1 mg/ml intermediate. For
itraconazole, the ECV determined after 24 h of incubation was
0.125 mg/ml for C. albicans, 0.25 mg/ml for Candida dubliniensis, and
0.5 mg/ml for other species, with the exception of C. krusei (1 mg/ml)
and C. glabrata (2 mg/ml). The ECV of ﬂucytosine was 0.5 to 1 mg/ml
for all species, aside from C. krusei (ECV 32 mg/ml). The ECV of
amphotericin B was 2 mg/ml for each species of Candida, as
determined by the CLSI method.8–10 Two reference strains, C. krusei
ATCC 6258 and C. parapsilosis ATCC 22019, were used as quality
control strains in each susceptibility test.
3. Results
3.1. Distribution of Candida species
In this study, we collected 132, 216, 178, 194, and 232 clinical
isolates of Candida species each year from 2009 to 2013,
respectively. The distribution of these Candida species is
presented in Table 1. Of the 952 isolates, C. albicans was the most
common species, accounting for 65.7% of the total isolates in our
study. C. glabrata (193, 20.3%) was the most frequently isolated
non-albicans Candida species, followed by C. tropicalis (84, 8.8%), C.
krusei (29, 3.0%), C. parapsilosis (13, 1.4%), and another three speciesTable 1
Distribution of 952 clinical isolates of Candida species from different specimens
Specimens C. albicans C. glabrata C. tro
Sputum (n = 519) 308 (49.3)a 148 (76.7) 53 (6
Urine (n = 242) 227 (36.3) 2 (1.0) 5 (6
Blood (n = 65) 30 (4.8) 14 (7.3) 6 (7
Throat swab (n = 29) 11 (1.8) 10 (5.2) 5 (6
Wound (n = 26) 19 (3.0) 3 (1.6) 2 (2
Pus (n = 12) 4 (0.6) 4 (2.1) 1 (1
Ascites (n = 11) 7 (1.1) 2 (1.0) 0 (0
Faeces (n = 9) 4 (0.6) 1 (0.5) 4 (4
Other sites (n = 39) 15 (2.4) 9 (4.7) 8 (9
Total 625 (65.7)b 193 (20.3) 84 (8
a The number of these isolates obtained from this specimen (the percentage of thes
b The number of clinical isolates of this Candida species (the percentage of these iso(8, 0.8%), including four isolates of Candida lusitaniae, two isolates
of Candida guilliermondii, and two isolates of C. dubliniensis.
When distributed according to the sources, the top three were
as follows: 519 (54.5%) isolates from sputum, 242 (25.4%) from
urine, and 65 (6.8%) from blood. There were also 29 (3.0%) Candida
isolates from throat swabs, 26 (2.7%) from wounds, 12 (1.3%) from
pus, 11 (1.2%) from ascites, nine (0.9%) from faeces, and 39 (4.1%)
from another 15 various specimens. By comparison, C. albicans was
also the most prevalent species of Candida isolated from urine
(227, 93.8%), sputum (308, 59.3%), and blood (30, 46.2%).
In order to describe the geographical distribution of clinical
isolates, we divided the regions in which the 36 hospitals were
located into three groups: the south (10 hospitals), the middle
(14 hospitals), and the north (12 hospitals). Among the 952 isolates,
35.7% were from the south region, 21.2% from the middle region,
and 43.1% from the north region. C. albicans accounted for 73.5% of
all Candida isolates from the south region, 44.1% from the middle
region, and 69.8% from the north region. C. glabrata accounted for
19.4% of all Candida isolates from the south region, 9.4% from the
middle region, and 26.3% from the north region.
The patients ranged in age from 8 months to 91 years (median
age 53 years), and these patients were divided into four groups by
age: <18 years, 18–44 years, 45–70 years, and >70 years. The
majority of C. albicans isolates (341, 54.6%) were collected from
patients aged 45–70 years. More C. glabrata were isolated from
patients in the age group >70 years than from the other age groups
(58.2% vs. 41.8%; p < 0.05).
3.2. Susceptibilities to azoles agents
The antifungal susceptibilities of all Candida species tested are
shown in Table 2. The MIC50 and MIC90 were deﬁned as the MICs at
which 50% and 90% of the total isolates were inhibited in growth,
respectively. Concerning the results of susceptibility testing to
azole agents, 7.6%, 3.2%, and 1.8% of the 952 isolates exhibited
decreased susceptibility to ﬂuconazole, voriconazole, and itraco-
nazole, respectively. Among these resistant isolates, four C.
albicans isolates and two C. tropicalis isolates were simultaneously
resistant to ﬂuconazole (MICs 8 mg/ml) and voriconazole
(MICs 1 mg/ml).
3.3. Susceptibilities to ﬂucytosine
Overall, 1.1% of the total isolates were considered resistant to
ﬂucytosine. As shown in Table 2, these ﬂucytosine-resistant
isolates were detected in all different common Candida species,
except for C. parapsilosis. There were ﬁve C. albicans isolates, two C.
glabrata isolates, one C. tropicalis isolate, and two C. krusei isolates
displaying reduced susceptibility to this agent on the basis of the
broth microdilution MICs.picalis C. krusei C. parapsilosis Other species
3.1) 7 (24.1) 2 (15.3) 1 (12.5)
.0) 4 (13.8) 3 (23.1) 1 (12.5)
.1) 7 (24.1) 5 (38.5) 3 (37.5)
.0) 3 (10.3) 0 (0) 0 (0)
.4) 1 (3.4) 0 (0) 1 (12.5)
.2) 2 (6.9) 1 (7.7) 0 (0)
) 1 (3.4) 0 (0) 1 (12.5)
.8) 0 (0) 0 (0) 0 (0)
.5) 4 (13.8) 2 (15.4) 1 (12.5)
.8) 29 (3.0) 13 (1.4) 8 (0.8)
e isolates in the same species).
lates in the total isolates).
Table 2
In vitro antifungal susceptibilities of 952 clinical isolates of Candida species as determined by the Clinical and Laboratory Standards Institute (CLSI) method
Candida species
(No. of isolates)
Antifungal agents MIC (mg/ml)a % Rb
Range 50% 90%
C. albicans Fluconazole 0.125–64 0.25 2 4.3
(625) Voriconazole 0.0313–4 0.125 0.25 2.1
Itraconazole 0.0078–0.5 0.0313 0.0625 1.3
Flucytosine 0.0625–8 0.0625 0.125 0.8
Amphotericin B 0.0313–2 0.25 0.25 1.1
C. glabrata Fluconazole 1–64 2 8 6.2
(193) Voriconazole 0.0313–2 0.0625 0.25 4.7
Itraconazole 0.125–8 0.5 1 2.1
Flucytosine 0.0313–4 0.25 0.25 1.0
Amphotericin B 0.125–1 0.25 0.5 0
C. tropicalis Fluconazole 0.125–32 0.5 1 10.7
(84) Voriconazole 0.0313–4 0.0625 0.25 7.1
Itraconazole 0.0313–2 0.0625 0.125 4.8
Flucytosine 0.0313–8 0.25 0.25 1.2
Amphotericin B 0.0625–1 0.25 0.5 0
C. krusei Fluconazole 16–>64 32 >64 75.9
(29) Voriconazole 0.125–8 0.25 1 6.9
Itraconazole 0.125–2 0.25 0.5 3.4
Flucytosine 2–32 4 16 6.9
Amphotericin B 0.0625–2 0.5 0.5 3.4
C. parapsilosis Fluconazole 0.125–8 0.25 2 15.4
(13) Voriconazole 0.0313–0.5 0.125 0.25 0
Itraconazole 0.0313–0.25 0.0625 0.0625 0
Flucytosine 0.0625–0.25 0.125 0.125 0
Amphotericin B 0.0625–1 0.125 0.25 0
Other species Fluconazole 0.125–4 0.25 1 0
(8) Voriconazole 0.0313–0.125 0.0313 0.0625 0
Itraconazole 0.0078–0.25 0.0625 0.0625 0
Flucytosine 0.0313–0.25 0.125 0.25 0
Amphotericin B 0.0313–1 0.25 0.5 0
MIC, minimum inhibitory concentration.
a 50% and 90% (MIC50 and MIC90) represent the MICs at which 50% and 90% of the total isolates are inhibited in growth, respectively.
b % R is the percentage of resistance for each Candida species.
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The range of amphotericin B MICs of the 952 isolates was from
0.0313 to 2 mg/ml, and the values of MIC90 were 0.25 and 0.5 mg/
ml for various Candida species (Table 2); this shows that
amphotericin B exhibited good activity in vitro against the
majority of the isolates (MICs <2 mg/ml). Nevertheless, some
isolates, including seven C. albicans and one C. krusei, had an
amphotericin B MIC of 2 mg/ml. None of eight unusual isolates
tested were classiﬁed as resistant to amphotericin B, with the MICs
ranging from 0.0313 to 1 mg/ml in this study.
4. Discussion
In this study, we investigated the distribution of species and
determined in vitro susceptibilities to antifungal agents of
952 clinical Candida isolates collected from 36 different hospitals
in Anhui, China from 2009 to 2013. Among the 952 clinical isolates,
a large proportion (54.5%) were isolated from sputum, followed by
urine (25.4%) and blood (6.8%). In contrast, the majority of Candida
isolates were most frequently obtained from urine (45.2%), then
blood (19.7%) and sputum (13%) in Taiwan, as documented in a
previous survey.11 C. albicans was the predominant species isolated
in our study, which is consistent with some reports.11,12 Moreover,
C. glabrata (20.3%) was the most prevalent non-albicans Candida
species in this region, which is in agreement with the results of the
studies conducted by Hazen et al.12 and Schmalreck et al.13
However, the most prevalent non-albicans Candida species was C.
parapsilosis in Latin America (25%), Canada (16%), and Europe
(17%),14 and C. tropicalis in Taiwan.11 This demonstrates that the
distribution of species differs from area to area.Overall, resistance to ﬂuconazole, voriconazole, and itraconazole
was seen in all the common Candida species, except for C. parapsilosis
with two ﬂuconazole-resistant isolates. None of four C. lusitaniae
isolates, two C. guilliermondii isolates, and two C. dubliniensis isolates
was resistant to the antifungal agents in our study. Of the
952 isolates, 7.6% exhibited decreased susceptibility to ﬂuconazole,
and its ratio was higher than other antifungal agents. The high
prevalence of ﬂuconazole resistance among Candida species may be
correlated with the increased use of ﬂuconazole in this area, as well
as in Korea.15Continuous exposure to azoles appears to have a major
impact in selecting ﬂuconazole-resistant Candida species, as
described previously.16 With regard to C. krusei, the reason for the
high-level resistance to ﬂuconazole (75.9%) is that C. krusei isolates
are inherently resistant to ﬂuconazole.9 Of note, we found four
isolates of C. albicans and two isolates of C. tropicalis with ﬂuconazole
MICs 8 mg/ml to be resistant to voriconazole. This phenomenon
highlights the important issue of cross-resistance among azole
agents. With regard to amphotericin B, its MIC90 values were
0.25 and 0.5 mg/ml for Candida species, and there were only seven C.
albicans and one C. krusei (0.8%) with an amphotericin B MIC of 2 mg/
ml. However, a German–Austrian multi-centre study showed nearly
11.2% of 1046 Candida isolates to be classiﬁed as amphotericin B-
resistant.13 This result reveals that the prevalence of antifungal
resistance in Candida isolates varies among different areas.
In conclusion, continuous surveillance of antifungal suscepti-
bilities in clinical isolates of Candida species at the national and
international levels is required in order to control the spread of
resistance and provide effective strategies for the prophylaxis and
treatment of humans with fungal infections. However, the reason
for the resistance trend of antifungal agents in our study is unclear.
This problem may be resolved by further studies on multiple
L. Zhang et al. / International Journal of Infectious Diseases 33 (2015) 1–44resistance mechanisms in combination with continuous surveil-
lance and extensive clinical evaluations.
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